title: Antiepileptic drugs and relapse after epilepsy surgery.
abstract: OBJECTIVE
  To evaluate whether the postoperative, antiepileptic drug (AED) regimen influences seizure recurrence after anterior temporal lobectomy when considering the putative mechanism of action and possible neuroprotective effects.
  
  
  METHODS
  This was a retrospective study. Patients who had an anterior temporal lobectomy for refractory epilepsy, whose preoperative MRI indicated mesial temporal sclerosis, were included. Postoperative AED regimens were compared with regard to seizure-outcome, considering the putative mechanism of action (sodium channel blockers, non-sodium channel blockers, and mixed mechanisms) or possible neuroprotective effect (levetiracetam, topiramate, tiagabine and zonisamide versus others). Time-to-event (first seizure after surgery) analysis was used to produce a Kaplan-Meier estimate of seizure recurrence, and groups were compared using Cox proportional hazard analysis.
  
  
  RESULTS
  226 patients (103 males and 123 females; mean age 42 +/- 11 years) were studied. The rates of postoperative seizure recurrence were not significantly different between the three groups regardless of the use of AEDs with different mechanisms of action (p = 0.23). Fifty patients were receiving possibly neuroprotective AEDs and 176 patients were not. Rates of seizure recurrence were not significantly different between these two groups either (p = 0.11). The differences between one-year seizure-free rates were not significant when we compared levetiracetam versus phenytoin or carbamazepine.
  
  
  CONCLUSIONS
  There appeared to be no advantage or disadvantage to either prescribing drugs with different mechanisms of action or using drugs with possible neuroprotective effect after temporal lobectomy. Prospective studies with larger sample sizes may be of benefit to further explore this issue.
authors.affiliation: Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. aliasadipooya@yahoo.com
authors.forename: Ali A
authors.initials: AA
authors.lastname: Asadi-Pooya
authors.forename: Maromi
authors.initials: M
authors.lastname: Nei
authors.forename: Ashwini D
authors.initials: AD
authors.lastname: Sharan
authors.forename: Scott
authors.initials: S
authors.lastname: Mintzer
authors.forename: Andro
authors.initials: A
authors.lastname: Zangaladze
authors.forename: James G
authors.initials: JG
authors.lastname: Evans
authors.forename: Christopher
authors.initials: C
authors.lastname: Skidmore
authors.forename: Michael R
authors.initials: MR
authors.lastname: Sperling
mesh_terms: D000328:Adult; D038481:Anterior Temporal Lobectomy; D000927:Anticonvulsants / Q000627:therapeutic use*; D004827:Epilepsy / Q000453:epidemiology / Q000517:prevention & control* / Q000601:surgery*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012306:Risk; D012598:Sclerosis; D055502:Secondary Prevention; D013702:Temporal Lobe / Q000473:pathology
chemical_list: D000927:Anticonvulsants; D018696:Neuroprotective Agents